# Darzalex Faspro

NDC: 57894-503
Generic name: daratumumab and hyaluronidase-fihj (human recombinant)
Labeler / Manufacturer: Janssen Biotech, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION
Routes: SUBCUTANEOUS
Marketing started: 20200501

FDA application: BLA761145

## Active ingredients

- DARATUMUMAB: 1800 mg/15mL
- HYALURONIDASE (HUMAN RECOMBINANT): 30000 U/15mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"57894-503"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=57894-503
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4bb241af-4299-4373-8762-2d6709515db0